Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

Yuan-Yuan Qu, Zhongquan Sun, Weiqing Han, Qing Zou, Nianzeng Xing, Hong Luo, Xuepei Zhang, Chaohong He, Xiao-Jie Bian, Jinling Cai, Chunxia Chen, Quanren Wang, Ding-Wei Ye, Yuan-Yuan Qu, Zhongquan Sun, Weiqing Han, Qing Zou, Nianzeng Xing, Hong Luo, Xuepei Zhang, Chaohong He, Xiao-Jie Bian, Jinling Cai, Chunxia Chen, Quanren Wang, Ding-Wei Ye

Abstract

Background: Dual blockade of immune checkpoint and angiogenesis is an effective strategy for multiple cancers. Camrelizumab is a monoclonal antibody against PD-1, and famitinib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenesis and antiproliferation activities against tumor cells. We conducted an open-label, multicenter phase 2 basket study of camrelizumab and famitinib in eight cohorts of genitourinary or gynecological cancers. Here, findings in cohort of advanced or metastatic urothelial carcinoma with platinum-progressive disease (cohort 2) are presented.

Methods: Patients who had progressed after platinum-based chemotherapy for advanced or metastatic disease or had progressed within 12 months after completion of platinum-based (neo)adjuvant therapy were given camrelizumab (200 mg intravenously every 3 weeks) plus famitinib (20 mg orally once daily). Primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1.

Results: Totally, 36 patients were recruited. With a median duration from enrollment to data cut-off of 11.9 months (range 6.1-28.5), ORR was 30.6% (95% CI 16.3% to 48.1%). Median duration of response (DoR) was 6.3 months (95% CI 2.1 to not reached). Median progression-free survival (PFS) was 4.1 months (95% CI 2.2 to 8.2), and median overall survival (OS) was 12.9 months (95% CI 8.8 to not reached). Patients with bladder cancer (n=18) had numerically better outcomes, with an ORR of 38.9% (95% CI 17.3% to 64.3%) and a median PFS of 8.3 months (95% CI 4.1 to not reached). Median DoR and OS in this subpopulation had not been reached with lower limit of 95% CI of 4.2 months for DoR and 11.3 months for OS, respectively. Of 36 patients, 22 (61.1%) had grade 3 or 4 treatment-related adverse events, mainly decreased platelet count and hypertension.

Conclusions: Camrelizumab plus famitinib showed potent antitumor activity in advanced or metastatic urothelial carcinoma patients after platinum-based chemotherapy. Patients with bladder cancer seemed to have better response to this combination.

Trial registration number: NCT03827837.

Keywords: Immunotherapy; Programmed Cell Death 1 Receptor; Therapies, Investigational; Urinary Bladder Neoplasms; Urologic neoplasms.

Conflict of interest statement

Competing interests: JC, CC, and QW are employees of Jiangsu Hengrui Pharmaceuticals. No other potential conflicts of interest were reported.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Figures

Figure 1
Figure 1
Clinical activity. (A) Best change in target lesion from baseline in all evaluable patients; (B) tumor responses over time. For the patient who achieved with complete response (CR), the target lesions included pathological lymph nodes, and thus the change in target lesions was not −100%. PR, partial response; SD, stable disease; PD, progressive disease.
Figure 2
Figure 2
Kaplan-Meier estimates of progression-free survival. (A) All patients; (B) subgroup by primary tumor types. NR, not reached.
Figure 3
Figure 3
Kaplan-Meier estimates of overall survival. (A) All patients; (B) subgroup by primary tumor types. NR, not reached.

References

    1. Stein JP, Lieskovsky G, Cote R, et al. . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75. 10.1200/JCO.2001.19.3.666
    1. Tripathi A, Plimack ER. Immunotherapy for urothelial carcinoma: current evidence and future directions. Curr Urol Rep 2018;19:109. 10.1007/s11934-018-0851-7
    1. Howlader N, Noone AM, Krapcho M, eds. SEER Cancer Statistics Review, 1975-2018. Bethesda, MD: National Cancer Institute, 2020.
    1. von der Maase H, Hansen SW, Roberts JT, et al. . Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068–77. 10.1200/JCO.2000.18.17.3068
    1. Sternberg CN, de Mulder PH, Schornagel JH, et al. . Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European organization for research and treatment of cancer protocol No. 30924. J Clin Oncol 2001;19:2638–46. 10.1200/JCO.2001.19.10.2638
    1. von der Maase H, Sengelov L, Roberts JT, et al. . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602–8. 10.1200/JCO.2005.07.757
    1. Sternberg CN, de Mulder P, Schornagel JH, et al. . Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;42:50–4. 10.1016/j.ejca.2005.08.032
    1. De Santis M, Bellmunt J, Mead G, et al. . Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30:191–9. 10.1200/JCO.2011.37.3571
    1. Bellmunt J, Théodore C, Demkov T, et al. . Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27:4454–61. 10.1200/JCO.2008.20.5534
    1. Petrylak DP, de Wit R, Chi KN, et al. . Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol 2020;21:105–20. 10.1016/S1470-2045(19)30668-0
    1. Bellmunt J, de Wit R, Vaughn DJ, et al. . Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26. 10.1056/NEJMoa1613683
    1. Powles T, Durán I, van der Heijden MS, et al. . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–57. 10.1016/S0140-6736(17)33297-X
    1. Sharma P, Retz M, Siefker-Radtke A, et al. . Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–22. 10.1016/S1470-2045(17)30065-7
    1. Patel MR, Ellerton J, Infante JR, et al. . Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018;19:51–64. 10.1016/S1470-2045(17)30900-2
    1. Mo H, Huang J, Xu J, et al. . Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 2018;119:538–45. 10.1038/s41416-018-0100-3
    1. Lou L, Mi Y, Xu Y. Preclinical antitumor study of famitinib, an orally available multi-targeted kinase inhibitor of VEGFR/PDGFR/c-Kit in phase I clinical trials. AACR, 2011.
    1. Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 2018;9:978. 10.3389/fimmu.2018.00978
    1. Almand B, Clark JI, Nikitina E, et al. . Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678–89. 10.4049/jimmunol.166.1.678
    1. Ozao-Choy J, Ma G, Kao J, et al. . The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009;69:2514–22. 10.1158/0008-5472.CAN-08-4709
    1. Agrawal S, Ganguly S, Hajian P, et al. . PDGF upregulates CLEC-2 to induce T regulatory cells. Oncotarget 2015;6:28621–32. 10.18632/oncotarget.5765
    1. Qu Y-Y, Zhang H-L, Guo H, et al. . Camrelizumab plus famitinib in patients with advanced or metastatic renal cell carcinoma: data from an open-label, multicenter phase II basket study. Clin Cancer Res 2021;27:5838–46. 10.1158/1078-0432.CCR-21-1698
    1. Xia L, Peng J, Lou G, et al. . Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study. J Immunother Cancer 2022;10:e003831. 10.1136/jitc-2021-003831
    1. Wu X, Xia L, Zhang Y. Famitinib malate plus camrelizumab in patients with recurrent platinum-resistant ovarian, Fallopian tube or primary peritoneal cancer: A multicenter, open-label, single-arm, phase II trial. In SGO 2020 Annual Meeting on Women’s Cancer. SGO 2020.
    1. Lin Y, Shih WJ. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics 2004;60:482–90. 10.1111/j.0006-341X.2004.00193.x
    1. Boorjian SA, Sheinin Y, Crispen PL, et al. . T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008;14:4800–8. 10.1158/1078-0432.CCR-08-0731
    1. Faraj SF, Munari E, Guner G, et al. . Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 2015;85:703.e1–703.e6. 10.1016/j.urology.2014.10.020
    1. Inman BA, Sebo TJ, Frigola X, et al. . PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 2007;109:1499–505. 10.1002/cncr.22588
    1. Gallagher DJ, Milowsky MI, Gerst SR, et al. . Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 2010;28:1373–9. 10.1200/JCO.2009.25.3922
    1. Cha EK, Shariat SF, Kormaksson M, et al. . Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2012;61:818–25. 10.1016/j.eururo.2012.01.021
    1. Stewart GD, Bariol SV, Grigor KM, et al. . A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int 2005;95:791–3. 10.1111/j.1464-410X.2005.05402.x
    1. Soria F, Shariat SF, Lerner SP, et al. . Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017;35:379–87. 10.1007/s00345-016-1928-x
    1. Matsumoto K, Novara G, Gupta A, et al. . Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2011;108:E304–9. 10.1111/j.1464-410X.2011.10188.x
    1. Yang K, Yu W, Liu H, et al. . Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder. Oncologist 2021;26:e1395–405. 10.1002/onco.13839
    1. Herbst RS, Arkenau H-T, Santana-Davila R, et al. . Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol 2019;20:1109–23. 10.1016/S1470-2045(19)30458-9
    1. Taylor MH, Lee C-H, Makker V, et al. . Phase IB/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors. J Clin Oncol 2020;38:1154–63. 10.1200/JCO.19.01598
    1. Marandino L, Raggi D, Calareso G, et al. . Cabozantinib plus Durvalumab in patients with advanced urothelial carcinoma after platinum chemotherapy: safety and preliminary activity of the open-label, single-arm, phase 2 Arcadia trial. Clin Genitourin Cancer 2021;19:457–65. 10.1016/j.clgc.2021.04.001
    1. Loriot Y, Grivas P, De Wit R. First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study. In ASCO Genitourinary Cancer Symposium. American Society of Clinical Oncology 2022.
    1. Xu R-H, Shen L, Wang K-M, et al. . Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial. Chin J Cancer 2017;36:97. 10.1186/s40880-017-0263-y
    1. Zhou A, Zhang W, Chang C, et al. . Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib. Cancer Chemother Pharmacol 2013;72:1043–53. 10.1007/s00280-013-2282-y
    1. Zhang W, Zhou A-P, Qin Q, et al. . Famitinib in metastatic renal cell carcinoma: a single center study. Chin Med J 2013;126:4277–81.
    1. Huang J, Xu B, Mo H, et al. . Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res 2018;24:1296–304. 10.1158/1078-0432.CCR-17-2439
    1. Huang J, Mo H, Zhang W, et al. . Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. Cancer 2019;125:742–9. 10.1002/cncr.31855
    1. Fang W, Yang Y, Ma Y, et al. . Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018;19:1338–50. 10.1016/S1470-2045(18)30495-9
    1. Nie J, Wang C, Liu Y, et al. . Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol 2019;37:1479–89. 10.1200/JCO.18.02151
    1. Qin S, Ren Z, Meng Z, et al. . Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol 2020;21:571–80. 10.1016/S1470-2045(20)30011-5
    1. Song Y, Wu J, Chen X, et al. . A single-arm, multicenter, phase II study of Camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res 2019;25:7363–9. 10.1158/1078-0432.CCR-19-1680
    1. Wang F, Qin S, Sun X, et al. . Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol 2020;13:47. 10.1186/s13045-020-00886-2
    1. Xu J, Zhang Y, Jia R, et al. . Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res 2019;25:515–23. 10.1158/1078-0432.CCR-18-2484
    1. Xu J, Shen J, Gu S, et al. . Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (rescue): a nonrandomized, open-label, phase II trial. Clin Cancer Res 2021;27:1003–11. 10.1158/1078-0432.CCR-20-2571

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj